Scotland medieval
Biotech

Braveheart files for IPO to support Hengrui-licensed cardio asset

Braveheart Bio isn’t letting Big Pharma take its freedom anytime soon as it aims for a Nasdaq listing to move its phase 3 cardiovascular drug forward.
Will Maddox Jul 15, 2026 1:40pm
Lead Pb on periodic table

With $315M raise, AdvanCell puts radiotherapy pedal to the metal

Jul 15, 2026 10:50am
Panther Rare Pharmacy

De-Risking a Rare Disease Launch Starts with Precision

Brought to you by PANTHERx® Rare Pharmacy
JNJ

J&J axes eye disease gene therapy after key phase 2b readout

Jul 15, 2026 10:26am
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: AdvanCell, Draig & more

Jul 15, 2026 9:00am
AAIC 2026

AAIC: Roche ‘very interested’ in tau despite amyloid AD focus

Jul 15, 2026 8:42am
More News

Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent

Jul 15, 2026 4:09am
Fierce Pharma

Celcuity set to be Big Pharma 'strategic target' after approval

Jul 14, 2026 4:56pm

FDA plans to release more CRLs as controversial policy resumes

Jul 14, 2026 2:50pm

Biogen defends anti-tau drug after stock slide

Jul 14, 2026 2:00pm